Project 2: The single agent efficacy of selective mutant BRAF inhibitors in patients with advanced melanoma is uniformly short-lived, illustrating that therapeutic resistance is a paramount question in the field. Recognizing that micro-environmental context influences the biological behavior of a tumor, including response to therapy, a systematic and comprehensive effort to identify mechanisms of resistance. Thus, Project 2 brings to this P01 the uses of refined germline and non-germline genetically engineered models of BRAF-driven melanomas for discovery and validation of novel resistant genes as well as for preclinical therapeutic testing of combinations that can overcome resistance to selective BRAF inhibitor (BRAFi) in melanoma. The following 3 aims will be pursued:
Aim 1 : Identify genetic events conferring resistance to BRAFi in vivo. Here, using our refined BRAF^(R)??^-driven genetically engineered mouse model (GEMM) ("iBIP"), we will generate a longitudinal cohort of sensitive and resistant melanomas upon long-term administration of BRAFi. These tumors will be subjected to deep genomic characterization to identify candidate lesions mediating resistance. Candidates will be prioritized and validated for/n wVo functional genetic screening based on statistical significance as well as evolutionary conservation through compahson with human genomic data from Project 1.
Aim 2 : Identify co-extinction targets for combination therapeutics against BRAF* melanoma. Complementing Aim 1, this aim will take a global and unbiased approach to the discovery of co-extinction targets. We will define the BRAF* regulated network in melanoma maintenance through kinetic transcriptome profiling of regressing melanomas upon genetic inactivation of mutant BF^F* in IBIP mice.
Aim 3 : Develop rational combination strategies for overcoming resistance to BRAFi in vivo. The goal of this aim is to generate sufficient preclinical efficacy data to motivate a novel Phase 18/11 clinical trial on a combination regimen that inhibits a co-extinction target along with BRAFi. Here, we will use mouse models to systematically screen potential combinations for efficacy;the best combination will then be tested in preclinical therapeutic trials in the IBIP GEMM.

Public Health Relevance

Resistance to selective BRAF inhibitors in melanoma is a paramount challenge in the clinics today. Thus, elucidating the mechanisms modulating response and conferring resistance is timely and relevant. Bringing to bear on this challenge cutting-edged genomics and computational science as well as refined genetically engineered mouse models enable a discovery effort that is unbiased and comprehensive.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Alves, Cleidson P; Yokoyama, Satoro; Goedert, Lucas et al. (2016) MYO5A gene is a target of MITF in melanocytes. J Invest Dermatol :
Kryukov, Gregory V; Wilson, Frederick H; Ruth, Jason R et al. (2016) MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351:1214-8
Xia, Yun; Li, Ying; Westover, Kenneth D et al. (2016) Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin. PLoS One 11:e0155217
Wang, Hequn; Osseiran, Sam; Igras, Vivien et al. (2016) In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Sci Rep 6:37986
Tirosh, Itay; Izar, Benjamin; Prakadan, Sanjay M et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189-96
Shen, Che-Hung; Kim, Sun Hye; Trousil, Sebastian et al. (2016) Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 22:1056-61
Friedman, Adam A; Amzallag, Arnaud; Pruteanu-Malinici, Iulian et al. (2015) Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One 10:e0140310
Kumar, Raj; Taylor, Michael; Miao, Benchun et al. (2015) BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol 135:1089-97
Kwong, Lawrence N; Boland, Genevieve M; Frederick, Dennie T et al. (2015) Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 125:1459-70
Zheng, Bin; Fisher, David E (2015) Metabolic vulnerability in melanoma: a ME2 (me too) story. J Invest Dermatol 135:657-9

Showing the most recent 10 out of 49 publications